Loading…
Based on limited metadata, this warning letter was issued to Invitrx Therapeutics, Inc., a biologics manufacturer, on November 9, 2022. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The warning relates to biologics products, which fall under FDA jurisdiction for manufacturing, quality control, and safety compliance. Additional details regarding the specific violations and regulatory deficiencies would require review of the complete warning letter.